In This Issue
Strut-based Brachytherapy: Favorable Outcomes at 5 Years
PROMIS Study: APBI Appropriate for “Unsuitable” Patients
BCS & ASTRO Recap: New SAVI Studies
BrachyBytes Editorial Advisory Board

Robert Kuske, M.D.

Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
Catheryn Yashar, M.D.
Vic Zannis, M.D.
Upcoming Events

San Antonio Breast Cancer Symposium 

December 9-13, 2014
San Antonio, TX

Become a Center of Excellence in APBI

Learn about becoming a Center of Excellence and find ways to grow your APBI program by reaching out to referring physicians and women in the community.

Contact for more information.  
Follow-up Links

Past Issues
Cianna Medical

BEST Forum
SAVI Sisters

UCSD Moores Cancer Center



September 2014  

Strut-based Brachytherapy with SAVI: Favorable Outcomes at 5 Years 
Catheryn Yashar, MD


At the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), researchers presented excellent five-year outcomes for the first 200 patients treated with the SAVI® applicator. The study is the most mature follow-up of the largest cohort of patients treated with strut-based brachytherapy to date.

Radiation oncologist Catheryn Yashar, MD, of UC San Diego’s Moores Cancer Center in La Jolla, Calif., is the co-principal investigator of the SCRG. She discusses the data, the study’s significance, and why she believes strut-based brachytherapy is the optimal method for delivering accelerated partial breast irradiation (APBI). Read more


PROMIS Study: APBI Appropriate for “Unsuitable” Patients

Women younger than 50 and those with positive lymph nodes – two groups previously considered ineligible for APBI by certain guidelines –  may be suitable for the treatment after all, according to a long-term retrospective study of breast cancer patients receiving APBI via interstitial brachytherapy.

Data from the PROMIS study presented at the 2014 ASTRO meeting showed low local recurrence rates for these patients at 10-years post-therapy, suggesting they no longer belong in the “unsuitable” category of the ASTRO guidelines for delivering APBI.

“Among many oncologists worldwide there is a misconception about the ASTRO APBI guidelines. They think the ‘unsuitable’ group was categorized based on poor APBI outcomes,” says Robert Kuske, MD, PROMIS principle investigator and Medical Director of Arizona Breast Cancer Specialists. “But, in reality, the criteria were established with data available in 2009…” Read more

BCS and ASTRO Recap: New Studies on Strut-based Brachytherapy

September was a busy month for the SAVI Collaborative Research Group (SCRG), as researchers presented the latest data on strut-based brachytherapy with SAVI at the annual Breast Cancer Symposium and ASTRO meetings.

At BCS, researchers reported excellent 5-year outcomes for the first 100 SAVI patients, including good local control and low toxcity. View poster

Deanna Attai, MD Discusses 5-Year Outcomes for APBI With Strut-Based Brachytherapy
Watch Deanna Attai, MD discuss 5-Year outcomes for APBI with strut-based brachytherapy

At ASTRO, similarly favorable 5-year results for the first 200 SAVI patients were presented, as well as a 3-year follow-up of nearly 600 patients. Both studies concluded strut-basedbrachytherapy is a “well-tolerated, effective treatment” for many women with early-stage breast cancer.
View 200 patient poster
View 596 patient poster

In addition, a single-institution study compared the dosimetric capabilities of the SAVI applicator to balloon-based brachytherapy catheters, which found the flexibility of the strut-based device was more effective than balloon-based devices in minimizing unnecessary radiation to the skin and ribs while maintaining effective tumor control. View poster